Efficacy and Safety of SHR0302 in Patients With Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, Phase 1b clinical study to evaluate the safety,
tolerability and anti-tumor efficacy of SHR0302 as monotherapy in patients with
relapsed/refractory peripheral T/NK cell lymphoma. Around 7-18 patients will be subsequently
enrolled into 3 different dose ascending cohorts. Additional 12-18 patients may be enrolled
to further explore a selected dose defined by dose escalation cohorts.